Table 2: Effect of inhibitors doxycycline and ECGC with and without PMA treatment on laryngeal squamous cell carcinoma (FaDu) and tongue cancer cells (SCC-25).
Larygneal squamous cell carcinoma (FaDu) | Tongue cancer cells (SCC-25) | |||
MMP-2 (%) | MMP-9 (%) | MMP-2 (%) | MMP-9 (%) | |
Doxycycline (μM) | ||||
Control | 7.1 | 7.5 | 12.4 | 14.1 |
10 | - | - | 15.9 | 20.2 |
25 | 6.6 | 22.3 | 6.5 | 13.8 |
50 | 0 | 53.7 | 0.6 | 12.2 |
100 | 0 | 2.8 | 0.3 | 4 |
Doxycycline (μM) with PMA (100 ng/ml) | ||||
Control | 0.2 | 0.3 | - | - |
10 | - | - | - | - |
25 | 0.1 | 87.6 | - | - |
50 | 0 | 11 | - | - |
100 | 0 | 0.1 | - | - |
EGCG (μg/ml) | ||||
Control | 2.3 | 5 | 16.1 | 13.7 |
10 | - | - | 22.1 | 31.5 |
25 | 3.1 | 15.2 | 10.4 | 4.8 |
50 | 1.5 | 42.6 | 0.4 | 1 |
100 | 0 | 96 | 0 | 0 |
EGCG (μg/mL) with PMA (100 ng/ml) | ||||
Control | 0.2 | 0.4 | 9.9 | 38.7 |
10 | - | - | 1.5 | 21 |
25 | 0.4 | 53.7 | 0.4 | 15.4 |
50 | 0.2 | 43.5 | 0 | 5.1 |
100 | 0 | 0.9 | 3.9 | 4 |